AZER-CEL OFF-THE-SHELF (ALLOGENEIC) CAR T
Why has Imugene management prioritised Azer-cel in the last 4 months presentations?
Are they quietly confident of the data to date, as they say, first-to-market potential,
currently in Phase 1b trial potential for registrational Phase 2/3 trial for FDA approval.
Azer-cel could be the first approved allogeneic CAR T therapy for patients with DLBCL who
failed autologous CAR T.
In addition to the above study, pre-clinical studies at City of Hope have started, combining Azer-cel with Imugene's onCARlytics (CF33-CD19), generating FDA data.
Deep dive into Allogeneic CAR T - recent article Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10814647/
Regards.
AZER-CEL OFF-THE-SHELF (ALLOGENEIC) CAR TWhy has Imugene...
-
- There are more pages in this discussion • 1,521 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.001(2.08%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.8¢ | 4.9¢ | 4.8¢ | $179.8K | 3.692M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 8124186 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3070575 | 9 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |